What's in Professor Francois Venter's pipeline?

Professor Francois Venter has 3 drugs in our index: 2 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Professor Francois Venter's portfolio?

Top competitors by shared drug class: Ain Shams University, Arbutus Biopharma Corporation, Australasian Gastro-Intestinal Trials Group, Casa Sollievo della Sofferenza IRCCS, Hospital Universitari Vall d'Hebron Research Institute.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/professor-francois-venter.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Professor Francois Venter — Portfolio Competitive Intelligence Brief

Professor Francois Venter pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Truvada	Truvada	marketed			Other
Atripla	Atripla	marketed			Other
KOCITAF	KOCITAF	phase 3	Antiviral	SARS-CoV-2 spike protein	Infectious Disease

Therapeutic area mix

Other · 2
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams University · 1 shared drug class
Arbutus Biopharma Corporation · 1 shared drug class
Australasian Gastro-Intestinal Trials Group · 1 shared drug class
Casa Sollievo della Sofferenza IRCCS · 1 shared drug class
Hospital Universitari Vall d'Hebron Research Institute · 1 shared drug class
Invivyd, Inc. · 1 shared drug class
JW Pharmaceutical · 1 shared drug class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Professor Francois Venter:

Cite this brief

Drug Landscape (2026). Professor Francois Venter — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/professor-francois-venter. Accessed 2026-05-16.